Clinical Pharmacology for the Office of Medicare Hearings and Appeals
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Health and Human Services (DHHS), Office of Mission Acquisition Solutions (OMAS), on behalf of the Office of Medicare Hearings and Appeals (OMHA), has issued a Presolicitation (Notice of Intent) to award a sole source contract to Elsevier Inc. for a Clinical Pharmacology Compendia Licenses Subscription. This action is justified by Elsevier's exclusive approval for Medicare Part B anti-cancer drug coverage determinations. Interested parties who believe they can fulfill this requirement must submit their capabilities by June 23, 2026, 12:00 PM ET.
Scope of Requirement
The government requires 32 licenses for access to the Clinical Pharmacology Compendium. This compendium is a recognized and reliable source of drug information, encompassing U.S. FDA-approved prescription medicines, over-the-counter medicines, dietary supplements, and investigational drug agents. Specifically, the database includes comprehensive listings of drugs and biologics used in the treatment and management of cancer patients in the United States.
Contract & Timeline
- Type: Presolicitation (Notice of Intent to Award Sole Source)
- Intended Awardee: Elsevier Inc.
- Justification: This procurement is being solicited from a single source under FAR 13.106-1(b). The Elsevier Clinical Pharmacology compendium has been exclusively approved for use by Administrative Law Judges and attorneys for making determinations on anti-cancer drug coverage under Medicare Part B regulations.
- Period of Performance: A twelve (12) month base period, with four (4) additional twelve (12) month option periods.
- Set-Aside: None (Sole Source)
- Published Date: June 9, 2026
Submission Instructions for Interested Parties
This notice is NOT a request for competitive proposals. However, interested parties who believe they can fulfill the requirement may identify their interest and capability. Responses must include clear and convincing evidence of capability and must be received by June 23, 2026, 12:00 PM Eastern Time.
- Submission Method: Electronic submission to Azeb Mengistu at azeb.mengistu@hhs.gov.
- Reference: Announcement number REQT-OMAS-PS-2026-00010.
- Required Information: Dun & Bradstreet Number (DUNS), Unique Entity Identifier (UEI) Number, Taxpayer Identification Number (TIN), and certification of business size.
- Registration: All respondents must have an active registration in the System for Award Management (SAM) at www.sam.gov.